Marketing-authorisation holder · United States
Liebel-Flarsheim
43 medicines in 3 countries, as authorisation holder and manufacturer.
Group structure
Part of
LiebelPharmaceutical groupOther companies in the group
Canada1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
1–25 of 43
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CONRAY60% · Injectable | Iotalamic acid | United States | Marketed | 1962 |
| CONRAY 3030% · Injectable | Iotalamic acid | United States | Not marketed | 1971 |
| CONRAY 4343% · Injectable | Iotalamic acid | United States | Not marketed | 1962 |
| CYSTO-CONRAY43% · Solution | Iotalamic acid | United States | Marketed | 1972 |
| CYSTO-CONRAY II17.2% · Solution | Iotalamic acid | United States | Marketed | 1972 |
| MD-76R66%; 10% · Injectable | Diatrizoate | United States | Not marketed | 1989 |
| MD-GASTROVIEW66%; 10% · Solution | Diatrizoate | United States | Marketed | 1981 |
| OPTIMARK16.545gm/50ml (330.9mg/ml) | 1654.5mg/5ml (330.9mg/ml) | 3309mg/10ml (330.9mg/ml) | 4963.5mg/15ml (330.9mg/ml) | 6618mg/20ml (330.9mg/ml) · Injectable | Gadoversetamide | United States | Not marketed | 1999 |
| OPTIMARK IN PLASTIC CONTAINER3309mg/10ml (330.9mg/ml) | 4963.5mg/15ml (330.9mg/ml) | 6618mg/20ml (330.9mg/ml) | 9927mg/30ml (330.9mg/ml) · Injectable | Gadoversetamide | United States | Not marketed | 1999 |
| OPTIRAY 16034% · Injectable | Ioversol | United States | Not marketed | 1988 |
| OPTIRAY 24051% · Injectable | Ioversol | United States | Not marketed | 1988 |
| OPTIRAY 30064% · Injectable | Ioversol | United States | Marketed | 1988 |
| OPTIRAY 30064 % / w/v · Solution | Ioversol | Canada | Not marketed | 1998 |
| OPTIRAY 300 (ULTRAJECT)64 % / w/v · Solution | Ioversol | Canada | Authorised | |
| OPTIRAY 32068% · Injectable | Ioversol | United States | Marketed | 1988 |
| OPTIRAY 32068 % / w/v · Solution | Ioversol | Canada | Not marketed | 1990 |
| OPTIRAY 320 (ULTRAJECT)68 % / w/v · Solution | Ioversol | Canada | Not marketed | 1995 |
| OPTIRAY 35074% · Injectable | Ioversol | United States | Marketed | 1988 |
| OPTIRAY 35074 % / w/v · Solution | Ioversol | Canada | Not marketed | 1993 |
| OPTIRAY 350 (ULTRAJECT)74 % / w/v · Solution | Ioversol | Canada | Not marketed | 1996 |
| OPTIMARK 0.5MMOL-ML SOLN. FOR I.V. INJ | Gadoversetamide | Saudi Arabia | Authorised | |
| OPTIMARK 0.5MMOL-ML SOLUTION For I.V. Injection* | Gadoversetamide | Saudi Arabia | Authorised | |
| OPTIMARK 0.5MMOL-ML SOLUTION For I.V. Injection* | Gadoversetamide | Saudi Arabia | Authorised | |
| OPTIMARK 0.5MMOL-ML SOLUTION For I.V. Injection* | Gadoversetamide | Saudi Arabia | Authorised | |
| OPTIMARK 0.5MMOL-ML SOLUTION For I.V. Injection* | Gadoversetamide | Saudi Arabia | Authorised |